COVID-19

Ronald T. Piervincenzi, PhD, CEO of US Pharmacopeia, explains how pharmacists and USP came together in 2021 to work harder than ever before, as well as what can be done now to prepare for the next health crisis.

Immunocompromised individuals are at a higher risk of developing severe symptoms and dying from COVID-19.

Ronald T. Piervincenzi, PhD, CEO of US Pharmacopeia, discusses the challenges that lie ahead as we move into the third year of the COVID-19 pandemic, as well as other major developments on the horizon for pharmacists in 2022.

Investigators in a clinical study evaluating the safety, tolerability, and immunogenicity of the Pfizer-BioNTech COVID-19 vaccine in children aged 6 months to under 5 years noted that their research will continue with new changes.

Study may help guide COVID-19 vaccination strategies for patients with blood disorders.

Study shows moderately reduced efficacy of the Moderna COVID-19 vaccine over time against Delta infection, which supports current booster dose recommendations.

A single booster dose of the GlaxoSmithKline and Sanofi recombinant adjuvanted COVID-19 vaccine candidate delivered consistent and strong immune responses.

The unique challenges that pharmacy learners encountered during the COVID-19 pandemic reinforce their importance in the professional pharmacy setting.

NRx Pharmaceuticals announces that no new concerns were identified by an independent data safety monitoring board, which recommends continued enrollment.

The findings are consistent with an interim analysis showing that the drug significantly reduced the risk of hospitalization or death for any cause by 89% compared with the placebo.

The study examined safety, immune response (immunogenicity), and adverse effects of 7 vaccines when used as a third booster jab.

Immunizations are very important for the winter season, and knowing how to gather safely for the holidays can make a big difference in staying healthy.

An FDA decision regarding Merck's COVID-19 oral antiviral is imminent, but a recent CMS decision could limit patient access.

Primary and secondary endpoints for which data are available were met in a trial dominated by variants.

Whether it's a mask falling off of your nose in the pharmacy or improper drive-thru etiquette, Dr. Mitch Lee has seen it all!

The emergency use authorization is based on the agency’s previous analysis of immune response data that supported use of a dose for individuals aged 18 years and older.

Studies are currently underway to determine the impact of the Omicron COVID-19 variant on the long-acting antibody combination.

Based on experience with other variants, Pfizer and BioNTech have high confidence that if needed, they can deliver an Omicron-based COVID-19 vaccine in March 2022.

Moderna COVID-19 vaccine found to offer an increased level of protection, including a 21% reduced risk of documented infection and 41% lower risk of hospitalization.

Administered 6 months after the 2-dose regimen of BNT162b2, boosting with the Johnson & Johnson vaccine shows a substantial increase in antibody and T-cell responses.

Nakia Eldridge, PharmD, MPH, senior manager of health care quality, safety, and information at US Pharmacopeia (USP), and Lindsey Clawson, MBA, USP’s lead of COVID-19 vaccine strategy, discuss the latest updates in USP’s COVID-19 Vaccine Handling Toolkit.

The investigators compared blood test results from a total of 186 paramedics, some of whom received their second dose less than 4 weeks after receiving the first, whereas others received second doses after 6 to 7 weeks.

Pharmacy utilization, patterns of utilization among hypothesized treatments for COVID-19, and medication utilization patterns were all impacted by the pandemic.

Sotrovimab demonstrated ongoing activity against all tested COVID-19 variants of concern and interest, as defined by the World Health Organization.

Studies support the use of a COVID-19 vaccine booster dose to increase protection among immunocompromised individuals.